Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk

AIM： To investigate the role that single nucleotide polymorphisms （SNPs） in the promoter of the tumour necrosis factor-alpha （TNF-α） gene play in the risk of inflammatory bowel diseases （IBDs） in a New Zealand population, in the context of international studies. METHODS： DNA samples from 388 patients with Crohn＇s disease （CD）, 405 ulcerative colitis （UC）, 27 indeterminate colitis （IC） and 201 randomly selected controls, from Canterbury, New Zealand were screened for 3 common polymorphisms in the TNF-α receptor： -238 G→A, -308 G→A and -857C→T, using a TaqmanR assay. A meta-analysis was performed on the data obtained on these polymorphisms combined with that from other published studies. RESULTS： Individuals carrying the -308 G/A allele had a significantly （OR = 1.91, χ2 = 17.36, P 〈 0.0001） increased risk of pancolitis, and a 1.57-fold increased risk （OR = 1.57, χ2 = 4.34, P = 0.037） of requiring a bowel resection in UC. Carrying the -857 C/T variant decreased the risk of ileocolonic CD （OR = 0.56, χ2 =4.32, P = 0.037）, and the need for a bowel resection （OR = 0.59, χ2 = 4.85, P = 0.028）. The risk of UC was reduced in individuals who were smokers at diagnosis, （OR = 0.48, χ2 = 4.86, P = 0.028）. CONCLUSION： TNF-α is a key cytokine known to play a role in inflammatory response, and the locus for the gene is found in the IBD3 region on chromosome 6p21, known to be associated with an increased risk for IBD. The -308 G/A SNP in the TNF-α promoter is functional, and may account in part for the increased UC risk associated with the IBD3 genomic region. The -857 C/T SNP may decrease IBD risk in certain groups. Pharmaco- or nutrigenomic approaches may be desir- able for individuals with such affected genotypes.